Balchem (BCPC) Stock Could Be 25% Undervalued On Cash Flow

Balchem shares have delivered a 38.7% return over the past three years, which naturally puts more focus on whether the current price still lines up with the cash the business can generate. With that kind of gain in the rear-view mirror, the question now is how today’s valuation stacks up against the company’s underlying cash flows.

• The 38.7% three year gain means a lot of future cash generation is now being implied by Balchem's share price, so assessing those cash flows has become more important for anyone considering the stock.
• Balchem's business model in ingredients and specialty products can shape expectations for long run cash conversion and reinvestment needs, which feeds directly into any estimate of intrinsic value based on future cash flows.
• If you'd rather focus on earnings, this one's for you. See why Balchem's 32.6x P/E tells a different valuation story.

The issue now is whether Balchem's current share price is properly supported by the cash flows implied by a Discounted Cash Flow (DCF) style intrinsic value estimate.

If you are weighing whether Balchem's 38.7% three year return is backed by its cash generation, it can help to compare it with a focused list of 30 high quality undervalued stocks.

Is Balchem a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes Balchem’s future cash generation and discounts it back to today in dollar terms. On the latest figures, the business produced last twelve month free cash flow of about $177.6m, which gives you a starting point that is already in solid positive territory rather than a turnaround story.

Analysts feeding into this DCF framework expect Balchem’s free cash flow to grow over time, with projections indicating a rising path through the next decade rather than flat or shrinking cheques to shareholders. When those future streams are discounted and added together, the DCF projections put Balchem's estimated intrinsic value meaningfully above the current share price of $168.24. This means the model suggests the market is not fully reflecting the current cash generation profile or the assumed growth in future free cash flows. Find out what Balchem could be worth using our Discounted Cash Flow (DCF) estimate.

The Balchem Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the DCF puzzle leaves off for Balchem. They spell out which combinations of future growth, margins and earnings would have to hold for the stock to be worth meaningfully more or meaningfully less than the current share price on the Community page. Each narrative treats Balchem's fair value as a specific thesis about how the business might develop over time, so you can watch that idea play out against real results.

Community narratives on Balchem split between those who see extra upside in the current setup and those who think expectations already look full.

Bull case: 19% undervalued

"The new state-of-the-art microencapsulation facility in New York is set to more than double Balchem's capacity in a high-growth, premium segment..."

Discover why this Narrative puts Balchem at 19% undervalued.

Bear case: roughly fairly valued

"While the new microencapsulation manufacturing facility in New York and capacity additions across segments are intended to support future demand, the risk of underutilized capacity during softer periods could raise depreciation and overhead per unit..."

Explore why this Narrative puts Balchem at roughly fairly valued.

Balchem's price is only half the story

You have the numbers on Balchem's cash flows and valuation, but the people directing those dollars and the way they are rewarded can tilt the risk and reward profile far more than any model suggests. See who runs Balchem and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com